This week, the European Commission proposed a “recalibration” of Supplementary Protection Certificates (SPCs) to boost investment in the development and manufacture of biosimilars and generics.
This week, the European Commission (EC) proposed a “recalibration” of Supplementary Protection Certificates (SPCs) to boost investment in the development and manufacture of biosimilars and generics.
An SPC is an intellectual property right that grants an extension of up to 5 years on a 20-year patent term for an innovative pharmaceutical. The goal of the SPC is to offset the loss of patent protection that occurs during the development and clinical trials of a generic or biosimilar. When it was first implemented, the SPC system sought to provide the pharmaceutical industry with sufficient incentives to develop innovative products within the European Union, and to prevent companies from relocating to other countries.
The new proposal seeks to amend the European Union’s legislation on SPCs to introduce a manufacturing exemption for export purposes during the term of an SPC. The exemption would restrict the protection conferred by the SPC in order to remove competitive disadvantages to EU-based generics and biosimilars manufacturers, namely by allowing a drug maker to manufacture a product in an EU member state for the sole purpose of exporting the product to a non-EU market (ie, a market that is not subject to an SPC).
According to the proposal, when in 2017, the EC launched a public consultation on SPCs, comments demonstrated broad support for the proposed waiver; while the SPC initially sought to spur innovation, the EC’s proposal notes that biosimilar and generic products will represent 80% of all medicines worldwide by volume in the year 2020, and SPCs keep EU-based manufacturers from producing any generics or biosimilars for a covered drug—even if the manufacture is exclusively for export to another market—during the protection period. “This problem puts EU-based industry at a disadvantage,” says the proposal, because manufacturers in non-EU countries do not fact the same restrictions.
Under the proposal, once an SPC has expired, biosimilar and generics companies who have established manufacturing lines for their export products will be able to use the same lines to manufacture products to supply the EU marketplace, an approach that the EC says will strengthen the EU supply chain.
The proposal notes that SPC protections will be left intact in the European Union, and that the EC will undertake a series of safeguards to ensure that products intended for export are not diverted to the EU market.
Enhancing Adoption of Infused Biosimilars for a Sustainable Future
October 30th 2024An IQVIA report highlights challenges to the sustainability of infused biosimilars in the US, citing rebate walls and reimbursement policies, and proposes key solutions to enhance adoption and benefits for all stakeholders.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Strengthening the Supply Chain: Key Insights From FDA Commissioner Dr Robert Califf
October 25th 2024At the GRx+Biosims conference, FDA Commissioner Robert Califf, MD, stressed the urgent need for data transparency in the global supply chain and the role of collaboration and artificial intelligence in ensuring the resilience of biosimilar and generic drug production.
FDA and Industry Experts Unpack Biosimilar Device Requirements
October 23rd 2024At the GRx+Biosims 2024 conference, a panel of industry experts and FDA officials discussed evolving device requirements for biosimilars and interchangeable biosimilars, highlighting new approaches to comparative use human factors studies, regulatory challenges, and alternative validation methods.